Result for
Topic: Vaccines and Immunity
April 15, 2021
Differences in COVID-19 Vaccine Concerns Among Asian Americans and Pacific Islanders: The COMPASS Survey
76% of respondents reported having one or more concerns about the COVID-19 vaccine in a cross-sectional national survey of Asian Americans and Pacific Islander (AAPI) adults in the US (n=1,646) conducted between October to December 2020. The most common concern was side effects (65%). In multivariable analyses, participant who were more likely to report more…
MRNA Vaccination Compared to Infection Elicits an IgG-Predominant Response with Greater SARS-CoV-2 Specificity and Similar Decrease in Variant Spike Recognition
[Pre-print, not peer-reviewed] Immune serological responses against SARS-CoV-2 among 55 recipients of the Pfizer-BioNTech vaccine were dominated by IgG antibody responses compared to more diverse responses (including IgM and IgA) elicited by natural infection among 100 COVID-19 patients. Vaccinated individuals also had decreased breadth of antibody response against endemic human coronaviruses compared to convalescent individuals….
Vaccination Boosts Protective Responses and Counters SARS-CoV-2-Induced Pathogenic Memory B Cells
[Pre-print, not peer-reviewed] SARS-CoV-2 specific B cells isolated from individuals who had recovered from SARS-CoV-2 infection appeared similar to B cells isolated previously described in individuals with chronic infections or inflammation (IgD negative, CD27 negative), according to a longitudinal study of convalescent individuals (n=22). After vaccination, the frequency of IgD/CD27 negative cells (“double negative”) decreased….
Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, in British Columbia, Canada
Surveillance for variants of concern (VOC) in British Columbia, Canada identified 77 VOC samples from 2,618 SARS-CoV-2 positive samples during January to March 2021 (57 B.1.1.7, 7 B.1.351, and 13 P.1 samples). This marked the first detection of the P.1 variant in British Columbia, and the 13 P.1 samples represented an epidemiologic cluster. Matic et…
Early T Cell and Binding Antibody Responses Are Associated with Covid-19 RNA Vaccine Efficacy Onset
In a cohort of 20 healthcare workers receiving the first dose of the Pfizer-BioNTech vaccine, SARS-CoV-2 spike-specific memory T-cell and binding antibody responses were universally detected prior to the time where vaccine efficacy is first detected in clinical trials (day 12). In contrast, receptor blocking and neutralizing antibodies were not detected on day 7 and…
Neutralizing Activity of Sputnik V Vaccine Sera against SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] Neutralizing antibody activity induced by SARS-CoV-2 adenovirus vector vaccine Sputnik V had geometric mean titers (GMT) that were reduced by 6.8-fold against a pseudovirus bearing B.1.351 spike protein mutations when compared to the prototypic D614G strain. GMT reduction was reduced by 2.8-fold against the pseudovirus with the E484K mutation alone. Among the…
Behavioral Nudges Increase COVID-19 Vaccinations Two Randomized Controlled Trials
[Pre-print, not peer-reviewed] Text-based behavioral nudges increased COVID-19 appointment and vaccination rates by 86% and 26%, respectively, in a randomized controlled trial conducted in patients from the University of California Los Angeles Health system (n > 110,000). In the experimental group, receiving text messages, including ownership messages (e.g “claim your dose”) increased the efficacy of…
Sera Neutralizing Activities against SARS-CoV-2 and Multiple Variants Six Month after Hospitalization for COVID-19
Neutralizing activity in sera of SARS-CoV-2 infected individuals (n=104) against the variants D614G, B.1.1.7, and P.1 up to 6 months after infection was similar compared to the prototypic strain isolated originally in Wuhan, but was reduced 3-fold against the B.1.351 variant. Similar to other studies, anti-spike and anti-nucleocapsid IgG levels waned over time (2.8% reverted…
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
Vaccine-elicited neutralizing antibody geometric mean titers (GMT) among healthcare workers who received the first dose of the Pfizer-BioNTech vaccine 1-2 months, 2-3 months, and more than 3 months after a prior SARS-CoV-2 infection were 437, 559, and 694 arbitrary units/mL, respectively. In contrast, healthcare workers with no prior infection had a GMT of 118 units/mL…
INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T Cell Activity Against Global SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] Neutralizing antibody activity induced by the SARS-CoV-2 vaccine candidate INO-4800 (Inovia Pharmaceuticals), a DNA-based vaccine, was reduced against variants of concern B.1.1.7 and B.1.351 compared to the wild-type strain by 2.1 and 6.9-fold, respectively. In contrast, neutralizing activity was maintained against the P.1 variant, which harbors the same E484K mutation as B.1.351…
Previous page Next page